A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies - Wikidata - wikimedia - TriplyDB

A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies

A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies

http://www.wikidata.org/entity/Q30431388

about

Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.UCN-01 induces S and G2/M cell cycle arrest through the p53/p21(waf1) or CHK2/CDC25C pathways and can suppress invasion in human hepatoma cell lines.Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner.Triple-negative breast cancer: new perspectives for targeted therapies.A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial.Potentiation of the novel topoisomerase I inhibitor indenoisoquinoline LMP-400 by the cell checkpoint and Chk1-Chk2 inhibitor AZD7762.Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.Chk'ing p53-deficient breast cancers UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response.Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma.Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.Checkpoint control and cancer.A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer.Molecular-targeted agents combination therapy for cancer: developments and potentials.Protein kinase C inhibitors: a patent review (2008 - 2009).Kinesin spindle protein (KSP) inhibitors in combination with chemotherapeutic agents for cancer therapy.Targeting Programmed Cell Death Using Small-Molecule Compounds to Improve Potential Cancer Therapy.Staurosporine analogs promote distinct patterns of process outgrowth and polyploidy in small cell lung carcinoma cells.Molecularly targeted therapies for p53-mutant cancers.Cooperative enhancement of radiosensitivity after combined treatment of 17-(allylamino)-17-demethoxygeldanamycin and celecoxib in human lung and colon cancer cell lines.An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.A Functional Signature Ontology (FUSION) screen detects an AMPK inhibitor with selective toxicity toward human colon tumor cells.Therapeutic landscape in mutational triple negative breast cancer

P2860

Q26745686-CEAA7B27-92BE-4D02-AF0E-BB15FBD5673A Q26864870-A30BDC66-11FE-4AE4-894F-4CBC418E6620 Q30422919-7AF75D6E-832E-4BC0-92B7-A88A15844CE9 Q34640744-AFF7A4AD-9873-4B5F-BF28-3259F7BC6880 Q34676703-A18CD2AD-1D5F-44C7-8C8F-3F95B7AE2C90 Q35001758-A088D0B8-BDBD-4C7D-9A88-A803E0311864 Q35751850-C7C9C345-3B7A-4B86-AD27-E9507A9BD25E Q35782905-87D0341F-6AA8-4A48-8619-EC2B254A6732 Q35858051-1764218F-CA0F-41F6-80DF-4E0A78CF9F2E Q35858171-927657F0-573F-4826-9BAF-80859DCE239A Q36048547-A95E8C05-A35F-4E4B-AA98-9C9FD8149705 Q36054977-8204D8E8-B63C-47AA-961F-0E9ABD917EFA Q36659343-79D25ECF-74EC-4DC2-A420-16F5E36A9169 Q36924445-DD4B5C0C-4A7C-4A73-B7AC-4AAC65CF3006 Q37941374-657606A8-7D46-4A27-9856-28E986159CD9 Q38091335-E11FE0C8-5F1A-4A15-83A2-2686C2A587AF Q38104670-E9B47A78-FD07-4470-B321-37375497D2D4 Q38116570-CCAC56B0-5219-4B99-9ADA-5DFAF97E34DE Q38130485-3B94C992-1285-43D2-9489-B84394E4DF73 Q38881119-8A4ED837-2BC8-4D31-B65C-56673C52903B Q38930827-54ABA661-1BAD-43AE-A5A4-28938BFF6227 Q39393193-513AE0B4-6283-4155-8222-7EBECE85DB8F Q39492343-3BCCE940-7CDF-42BE-8301-9B05414B4946 Q45327842-0B61984E-E41A-420B-9636-DC27FEC50737 Q52680663-5A591A32-64BD-47FB-A363-BFAFB9394FE2 Q57109569-B87CB4A2-9B8A-4FE5-B9FB-4E1C3986CCBE

P2860

A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies

http://www.wikidata.org/entity/Q30431388

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

A Phase 1 study of UCN-01 in c ...... stant solid tumor malignancies

@ast

A Phase 1 study of UCN-01 in c ...... stant solid tumor malignancies

@en

type

label

A Phase 1 study of UCN-01 in c ...... stant solid tumor malignancies

@ast

A Phase 1 study of UCN-01 in c ...... stant solid tumor malignancies

@en

prefLabel

A Phase 1 study of UCN-01 in c ...... stant solid tumor malignancies

@ast

A Phase 1 study of UCN-01 in c ...... stant solid tumor malignancies

@en

P1433

Q30431388-B37A5127-7E1C-4B37-9A3B-D9CE40CC9F50

P1476

Q30431388-DCB2E147-AE7D-45A7-9ACA-8BBA5CB5BBE5

P2093

Q30431388-0C3EEBF9-E42F-4380-BE4A-792EACCD6281

Q30431388-1B917551-3572-4480-B726-5EF897C9E23F

Q30431388-1E5458D7-CF4A-4486-AD7A-7FDBE629D35F

Q30431388-282B657A-EAB5-4F2B-AEAB-3882C6004FCF

Q30431388-325E3478-78AA-4D21-834D-1E7D288A05FA

Q30431388-49BDE230-0FED-4D20-B550-2A5B8B070F91

Q30431388-4C237E9E-D199-4D69-98FC-0FD4AD3941DD

Q30431388-4DAF291B-4969-43CF-ADBF-DF55D3A331A7

Q30431388-523A85A1-CE38-44A1-8510-E08AE8CE824F

Q30431388-5A998F08-8E33-410C-870F-160767F3A914

P2860

Q30431388-0C41094A-0198-48EB-80FC-34E9DDC98DCB

Q30431388-1C49038F-B0BD-4721-99AC-92019B9720E7

Q30431388-2495A23C-F14B-4692-BC8C-B0B0BEA19E0A

Q30431388-26366149-FE50-4EBC-BC71-790F63EC0F4F

Q30431388-2DCC28B2-32DF-4626-B73C-74F75154A300

Q30431388-2E435173-F00F-421B-87BB-2356B5567B5A

Q30431388-3130AB35-8991-4D1C-A914-9EEC7CDE0000

Q30431388-34BDEDD7-7BDC-488D-B83E-EF0B48D25F7E

Q30431388-3F1EF617-6794-4BC0-8705-DA8E5B7B2108

Q30431388-3FFB8D54-838C-41BC-B09C-D95A80E2DBD5

P2888

Q30431388-684DEFAF-F76A-4AD5-8C3A-C7796BC798F8

P304

Q30431388-53E977D8-8CC4-4BDF-BFC8-D7EF4357CF68

P31

Q30431388-6AB0FE6B-50C7-4A6F-AC9B-41C502178467

P356

Q30431388-F951E60C-7DC4-438C-874F-A728BF9D26FB

P433

Q30431388-763AAE7B-068B-4BE8-A33D-BE9116D0710B

P478

Q30431388-19FD7B5A-CC57-4D2D-848E-3088613EE462

P577

Q30431388-BFE65AE9-9EF7-4872-BAB2-3194CB07D423

P5875

Q30431388-DFF45A67-0B1A-4D0A-AA5E-C7DE2433D55E

P6179

Q30431388-72B21245-9C9E-4ADC-BE83-0EA5F4A0D896

P698

Q30431388-3E7692AF-8548-4533-8FE2-52BD5E122988

P932

Q30431388-332964A0-2E51-42E0-9AAB-CD8AF48CBBCE

P356

S00280-010-1410-1

P1433

Cancer Chemotherapy and Pharmacology

P1476

A Phase 1 study of UCN-01 in c ...... stant solid tumor malignancies

@en

P2093

Allison N Creekmore

http://www.w3.org/2001/XMLSchema#string

Benjamin R Tan

http://www.w3.org/2001/XMLSchema#string

Christine E Ryan

http://www.w3.org/2001/XMLSchema#string

Cynthia X Ma

http://www.w3.org/2001/XMLSchema#string

Douglas R Adkins

http://www.w3.org/2001/XMLSchema#string

Eliane M Soares

http://www.w3.org/2001/XMLSchema#string

Helen Piwnica-Worms

http://www.w3.org/2001/XMLSchema#string

Howard L McLeod

http://www.w3.org/2001/XMLSchema#string

James W Fleshman

http://www.w3.org/2001/XMLSchema#string

Janet Dancey

http://www.w3.org/2001/XMLSchema#string

P2860

PDK1, the master regulator of AGC kinase signal transduction

Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours

Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway.

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Repeated observation of breast tumor subtypes in independent gene expression data sets

The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1

P2888

s00280-010-1410-1

P304

1225-1237

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-010-1410-1

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P577

2010-08-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45539245

http://www.w3.org/2001/XMLSchema#string

P6179

1044271677

http://www.w3.org/2001/XMLSchema#string

P698

20694727

http://www.w3.org/2001/XMLSchema#string

P932

3102212

http://www.w3.org/2001/XMLSchema#string